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Nuclear receptor co-repressor (N-CoR) is the key component of generic co-repressor 
complex essential for the transcriptional control of genes involved in cellular hemostasis. 
We have recently reported that N-CoR actively represses Flt3, a key factor of hema-
topoietic stem cells (HSC) self-renewal and growth, and that de-repression of Flt3 by 
the misfolded N-CoR plays an important role in the pathogenesis of promyelocytic and 
monocytic acute myeloid leukemia (AML). The leukemic cells derived from the promyelo-
cytic and monocytic AML are distinctly characterized by the ectopic reactivation of stem 
cell phenotypes in relatively committed myeloid compartment. However, the molecular 
mechanism underlying this phenomenon is not known. Here, we report that N-CoR 
function is essential for the commitment of primitive hematopoietic cells to the cells of 
myeloid lineage and that loss of N-CoR function due to misfolding is linked to the ecto-
pic reactivation of generic stem cell phenotypes in promyelocytic and monocytic AML. 
Analysis of N-CoR and Flt3 transcripts in mouse hematopoietic cells revealed a positive 
correlation between N-CoR level and the commitment of myeloid cells and an inverse 
correlation between N-CoR and Flt3 levels in primitive as well as committed myeloid 
cells. Enforced N-CoR expression in mouse HSCs inhibited their growth and self-renewal 
potentials and promoted maturation toward cells of myeloid lineage, suggesting a role of 
N-CoR in the commitment of cells of myeloid lineage. In contrast to AML cells with natively 
folded N-CoR, primary and secondary promyelocytic and monocytic AML cells harbor-
ing the misfolded N-CoR were highly positive for Flt3 and myeloid antigen-based HSC 
marker CD34. Genetic and therapeutic restoration of N-CoR conformation significantly 
down-regulated the CD34 levels in monocytic AML cells, suggesting an important role of 
N-CoR in the suppression of CD34-based HSC phenotypes. These findings collectively 
suggest that N-CoR is crucial for the commitment of primitive hematopoietic cells to 
cells of myeloid lineage and that misfolded N-CoR may contribute to transformation 
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introduction
Balanced transcriptional control of self-renewal and lineage-
specific genes by the coordinated actions of co-activator and 
co-repressor proteins and sequence-specific transcriptional factors 
plays an important role in the normal growth and maturation of 
hematopoietic cells. During the highly regulated process of com-
mitment of primitive myeloid cells in the hematopoietic system, 
the co-activator proteins confer the specific lineage identity by trig-
gering the expression of genes essential for lineage commitment, 
whereas the co-repressor proteins concurrently suppress the cel-
lular self-renewal potentials by actively repressing the self-renewal 
genes (1). Thus, the maturation and commitment of primitive 
hematopoietic cells is achieved through the coordinated actions of 
these co-activator and co-repressor proteins, and any imbalance 
in this coordination could alter the linear growth and maturation 
of hematopoietic cells, ultimately leading to malignant growth and 
transformation in AML (acute myeloid leukemia). One of the key 
components of the generic co-repressor protein complex essential 
for the transcriptional repression of various growth-promoting 
genes, including the self-renewal genes, is nuclear receptor co-
repressor (N-CoR), which was first identified as a co-repressor of 
unliganded nuclear hormone receptors (2, 3). We have previously 
shown that N-CoR is a direct target of heterogeneous oncogenic 
insults such as fusion oncogenes created by chromosomal trans-
locations, which trigger a nearly homogenous change in N-CoR 
conformation through aberrant post-translational modification, 
ultimately leading to its misfolding and premature loss in pro-
myelocytic and monocytic AML, two distinct subtypes of AML 
characterized by maturation arrest of intermediate myeloid cells 
(4–9). As shown by us, the N-CoR misfolding in monocytic AML-
derived primary and secondary leukemic cells was actually trigged 
by Akt-induced phosphorylation of N-CoR at the consensus Akt 
motif located in the c-terminal domain of N-CoR protein (9). We 
have also demonstrated that Flt3, the cytokine receptor essential for 
the self-renewal of primitive hematopoietic cells (10, 11), is actively 
repressed by N-CoR and that misfolding and premature loss of 
N-CoR protein leads to the de-repression of Flt3 in promyelocytic 
and monocytic AML-derived primary and secondary leukemic 
cells (8). These findings suggested that N-CoR-mediated tran-
scriptional repression of stem cell genes like Flt3 might be crucial 
for the suppression of self-renewal potential of hematopoietic cells 
during their commitment and differentiation to cells of myeloid 
lineage and that de-repression of Flt3 due to N-CoR misfolding 
may contribute to formation of leukemia-initiating cells (LICs) 
or leukemic stem cells (LSCs) through the ectopic reactivation of 
self-renewal potentials in relatively matured cells.
Although AML is increasingly being recognized as a stem cell 
disorder, the true origin of LSCs in AML is still a matter of debate. 
It is not clear whether LSCs in AML are initiated in the primitive 
hematopoietic stem cell compartment or they merely represent a 
re-acquisition of stem cell-like characteristics in relatively commit-
ted myeloid cells. Several studies in mice have suggested that LICs 
in promyelocytic AML could arise in the committed progenitor 
cells (12–15). Likewise, it has recently been shown that some 
monocytic AML-specific chromosomal translocations impart 
stem cell-like properties only on the committed progenitor cells 
and that LSCs in monocytic AML are initiated in the matured 
myeloid cell compartment when these matured cells ectopically 
regain the stem cell-like properties (16, 17). However, how these 
so-called stem cell-like properties are kept in check when the 
primitive hematopoietic cells progress toward commitment and 
maturation and how exactly these properties are temporally 
reactivated or unmasked in promyelocytic and monocytic AML 
are not known. One of the important and most basic phenotypes 
based on which both the normal hematopoietic stem cells and 
LSCs in various AML subtypes are characterized is the cell surface 
expression of myeloid antigen-based stem cell marker CD34. As 
with the activity of hematopoietic stem cells, the LSC activity 
in some specific subtypes of AML are also contained within the 
CD34+ fraction of AML cells (18–22), making it a fundamental 
stem cell marker for both HSCs and LSCs. However, leukemic cells 
derived from various AML subtypes display significant heteroge-
neity based on CD34 level. Here, we report that transcriptional 
repression mediated by N-CoR is essential for the suppression of 
growth and self-renewal potentials of HSCs and that loss of N-CoR 
function due to misfolding leads to ectopic reactivation of Flt3 and 
CD34-based hematopoietic stem cell phenotypes in promyelocytic 
and monocytic AML. These findings suggest that transcriptional 
repression mediated by N-CoR might be crucial for the suppres-
sion of self-renewal potentials of primitive hematopoietic cells 
during their commitment and maturation to cells of myeloid 
lineage, and abrogation of this repression due to the misfolding 
and premature loss of N-CoR may contribute to the formation of 
LSC or LIC through the ectopic reactivation of CD34+/Flt3+-based 
stem cell phenotype in promyelocytic and monocytic AML.
results
n-cor inhibits the self-renewal Potential of 
Primitive hematopoietic cells
We have recently shown that natively folded N-CoR actively 
represses the Flt3 gene and that misfolded conformation-
dependent loss of N-CoR leads to up-regulation of Flt3 in leuke-
mic cells derived from promyelocytic and monocytic AML (8). 
To understand the significance of N-CoR-induced transcriptional 
repression of Flt3 in the normal growth and maturation of primi-
tive hematopoietic cells, we first determined the levels of N-CoR 
of committed myeloid cells through the ectopic reactivation of Flt3/CD34-based stem 
cell phenotypes in promyelocytic and monocytic AML. Moreover, these findings provide 
novel mechanistic insights into the formation of leukemic stem cells in subsets of AML 
and identify the misfolded N-CoR as a subtype-specific biomarker of AML.
Keywords: aMl, ncor, misfolded protein, Flt3, cD34, lscs
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and Flt3 transcripts in mature and immature hematopoietic cells 
isolated from mouse bone marrow. Using multiparameter flow 
cytometry, these hematopoietic cells at various stages of develop-
ment were isolated based on the expression of lineage-specific cell 
surface markers, and the level of N-CoR and Flt3 transcripts in 
each isolated cell type was determined by real-time PCR analysis. 
As shown in Figure 1, the level of Flt3 transcript in c-kit+ imma-
ture hematopoietic cells was significantly higher when compared 
with the level of N-CoR transcript. By contrast, the level of N-CoR 
transcript was significantly higher in relatively matured hemat-
opoietic cells such as monocytes, granulocytes, and erythrocytes, 
in which the level of Flt3 transcript is significantly low (Figure 1). 
These findings suggested an inverse correlation between N-CoR 
and Flt3 expression during the growth and maturation of mouse 
hematopoietic cells. The gradual increase in N-CoR transcript 
level as the primitive hematopoietic cells progressed to maturation 
toward cells of myeloid lineage suggested a possible link between 
N-CoR expression and the maturation of primitive hematopoietic 
cells to cells of myeloid lineage. The inverse correlation in N-CoR 
and Flt3 levels observed in myeloid compartment was not quite 
evident in lymphoid compartment such as double-negative or 
CD4-positive lymphocytes derived from thymus (Figure 1). To 
further explore the role of N-CoR in the commitment of cells of 
myeloid lineage, the functional effect of ectopic N-CoR on the 
growth and maturation of c-kit+ hematopoietic cells, in which 
N-CoR was barely detected, was determined. First, mouse bone 
marrow cells were infected with retrovirus-based N-CoR expres-
sion plasmid MSCV-IRES-GFP-N-CoR or control empty vector 
MSCV-IRES-GFP. Next, virus-infected c-kit+ bone marrow cells 
were purified using c-kit+ antibody and GFP signal employing 
fluorescence-activated cell sorting (FACS). Finally, the growth and 
maturation of FACS-purified c-kit+ N-CoR-infected cells were 
compared with that of c-kit+ vector-infected cells through various 
functional assays as outlined in Figure 2A. First, to assess whether 
enforced N-CoR expression in the primitive hematopoietic cells 
could inhibit their growth and proliferation, 1 × 104 FACS-purified 
FigUre 1 | levels of n-cor and Flt3 transcripts in purified mouse 
hematopoietic cells. Levels of N-CoR and Flt3 transcripts in total bone 
marrow as well as in each purified subtypes of mouse hematopoietic cells 
were determined by real-time RT-PCR analysis. The values presented in the 
graph are average of three independent experiments.
c-Kit+ and GFP-positive cells were plated on methylcellulose 
medium and their growth was monitored by counting the num-
ber of colonies that grew in size due to the proliferation of cells. 
After 10 days of culture on methylcellulose medium, the MSCV-
IRES-GFP-N-CoR-infected c-Kit+ cells made significantly fewer 
colonies when compared with cells infected with empty vector 
MSCV-IRES-GFP, suggesting that ectopic N-CoR might have 
suppressed the growth and proliferation of these cells (Figure 2B, 
upper panels). More significantly, morphological analysis of cells 
isolated from N-CoR- or vector-infected colonies revealed that 
N-CoR-infected colonies were highly enriched with matured 
myeloid cells when compared with colonies of vector-infected 
cells, suggesting a role of ectopic N-CoR in the maturation of 
hematopoietic cells to myeloid lineage (Figure 2B, lower panels). 
Next, to test whether enforced N-CoR expression in primitive 
hematopoietic cells could inhibit their self-renewal potentials at 
the expense of lineage commitment, the morphology of MSCV-
IRES-GFP-N-CoR-infected c-Kit+ cells cultivated on OP9 stroma 
in the presence of GSCF, IL3, SCF, and EPo was analyzed through 
long-term culture-initiating cell (LTC-IC) assay. The LTC-IC assay 
is a well-established in vitro assay that measures the self-renewal 
and differentiation potentials of the primitive hematopoietic cells 
(23). LTC-ICs present in purified cell suspensions and co-cultured 
on a supportive feeder layer are detected by their sustained ability 
to produce hematopoietic progenitors (colony-forming cells) after 
around 4 weeks of culture. In the LTC-IC assay performed with 
FACS-purified MSCV-IRES-GFP-N-CoR or MSCV-IRES-GFP 
cells, the MSCV-IRES-GFP-N-CoR-infected cells generated 
significantly higher number of granulocyte (G) and macrophage 
(M) colonies when compared with cells infected with empty 
vector MSCV-IRES-GFP (Figure 2C). While MSCV-IRES-GFP-
N-CoR-infected cells also generated slightly higher number of 
granulocyte–macrophage (GM) colonies, they produced signifi-
cantly lower number of mixed or GEMM (granulocyte/erythroid/
monocyte/megakaryocyte) colonies which are enriched in 
multipotent progenitor cells. These findings suggest that N-CoR 
may exert its role downstream of GEMM development. Next, we 
compared the morphology of MSCV-IRES-GFP-N-CoR-infected 
cells of LTC-IC assay with the cells infected with empty vector. 
As shown in Figure 2D, significantly higher number of myeloid 
lineage cells were present in MSCV-IRES-GFP-N-CoR-infected 
colonies when compared with colonies infected with empty vec-
tor (Figure 2D). Together, these findings suggested that enforced 
N-CoR expression in c-Kit+ primitive hematopoietic cells signifi-
cantly reduced their self-renewal potentials and promoted their 
maturation to cells of myeloid lineage.
n-cor inhibits the repopulating Potential of 
Primitive hematopoietic cells
One of the important functional properties based on which 
hematopoietic stem cells are characterized is their ability to 
repopulate the host hematopoietic system after transplantation 
in immunocompromised mice. Therefore, to determine if N-CoR 
could inhibit the ability of c-kit+ primitive hematopoietic cells 
to repopulate the hematopoietic system in vivo, a bone marrow 
transplantation assay was performed in immunosuppressed 
mice. 5  ×  105 FACS-purified MSCV-IRES-GFP-N-CoR or 
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vector-infected cells were implanted intravenously into suble-
thally irradiated recipient mice and the number of GFP-positive 
cells in the peripheral blood of the recipient mice was analyzed by 
FACS at the interval of 3, 6, and 9 weeks. From 3 weeks onward, the 
number of GFP-positive cells in the peripheral blood of N-CoR 
transplanted mice was significantly lower when compared with 
mice transplanted with control vector (Figure 3), suggesting that 
enforced N-CoR expression in the primitive hematopoietic cells 
significantly reduced their ability to repopulate the hematopoi-
etic system. These findings suggested that N-CoR could play an 
important role in the suppression of self-renewal potentials of 
primitive hematopoietic cells in vivo.
Misfolded n-cor is linked to the reactivation 
of cD34+/Flt3+-Based stem cell Phenotype in 
Promyelocytic and Monocytic aMl
Our findings thus far suggested a possible role of N-CoR in the 
suppression of self-renewal and growth potentials of primitive 
hematopoietic cells, which might be necessary for their eventual 
commitment and maturation to cells of myeloid lineage. The 
suppression of this self-renewal and growth potentials by N-CoR 
might be a net outcome of N-CoR-mediated transcriptional 
FigUre 2 | enforced n-cor expression in c-Kit+ stem cell/progenitor cells inhibits their growth and promotes commitment toward myeloid lineage. 
(a) Schematic representation of the experiments performed with mouse bone marrow cells transduced with N-CoR or control vector. (B) Enforced N-CoR expression 
in c-Kit+ stem cell/progenitor cells inhibits their self-renewal potential. The growth and commitment of mouse primitive hematopoietic cells transduced with 
MSCV-IRES-GFP-N-CoR or empty vector were determined in colony formation assay and Wright–Giemsa staining. The number of colonies derived from vector or 
N-CoR-infected cells (left panel) was counted and data were plotted as bar graph (right panel). Asterisk represents statistical significance in Student’s t-test, 
p < 0.01. Error bars indicate mean ± SD. (c) Colony-forming unit (CFU)-culture assay: the number of granulocyte (G), macrophage (M), granulocyte–macrophage 
(GM), and mixed colonies (granulocyte, erythroid, monocyte, and megakaryocyte) formed by GFP- and c-Kit-positive cells treated with G-CSF in methylcellulose 
medium for 10 days was scored and plotted as bar graph. Asterisks represent statistical significance in Student’s t-test, p < 0.01. Error bars indicate mean ± SD.  
(D) Morphology of purified mouse bone marrow cells transduced with MSCV-IRES-GFP-N-CoR or control vector was determined with Wright–Geimsa staining where 
eosinophils (Eos), mast cells (MC), meta-myelocytes (Met), monocytes (Mono), myelocytes (M), neutrophils (N), and promyelocytes (PM) are labeled (right panel).
repression of stem cell self-renewal genes like Flt3. If true, then loss 
of N-CoR function due to misfolding may lead to de-repression 
of stem cell self-renewal genes like Flt3 and eventual reactiva-
tion of stem cell phenotypes in promyelocytic and monocytic 
AML. We have previously reported that primary and secondary 
leukemic cells derived from promyelocytic and monocytic AML 
harbor a distinctly misfolded and non-functional N-CoR protein 
while the N-CoR presented in leukemic cells derived from other 
AML subtypes is natively folded and functionally stable (6–9). 
We have further shown that a natively folded N-CoR actively 
represses Flt3, the key regulator of the stem cell phenotype and 
self-renewal potentials in primitive hematopoietic cells, and that 
misfolding of N-CoR is directly linked to up-regulation of Flt3 
in promyelocytic and monocytic AML cells (8). Besides Flt3, 
the basic stem cell phenotype in the hematopoietic system is 
characterized by the cell surface expression of myeloid antigen-
based stem cell marker CD34. In clinical AML studies, the overall 
CD34 positivity of a specific AML subtypes is largely defined by 
the presence of at least 10–20% CD34-positive cells determined 
by FACS (24, 25). Therefore, to test if misfolding of N-CoR leads 
to the unmasking of stem cell-like phenotypes in promyelocytic 
and monocytic AML, the relative “stemness” (CD34+/Flt3+ 
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phenotype) of promyelocytic and monocytic AML-derived 
cells was compared with that of non-promyelocytic–monocytic 
AML cells in which N-CoR is not misfolded. In standardized 
FACS assay, the CD34 positivity of promyelocytic AML-derived 
cells (NB4; 41.0%) and monocytic AML-derived cells [THP-1 
(72.2%), Nomo-1 (18.9%), MV4-11 (40.9%), SigM5 (15.3%), 
and MM-1 (66.0%)] (Figure 4A) was significantly higher than 
minimum accepted level of 10–20% CD34 positivity for AML. 
By contrast, the CD34 positivity of U937 and HL-60 cells, two 
non-promyelocytic/monocytic AML-derived cells that harbor 
natively folded and fully functional N-CoR protein, was only 0.4 
and 2.1%, respectively (Figure 4A). Consistent with our previous 
finding, all the CD34-positive promyelocytic and monocytic 
AML-derived cells harbored a distinctly misfolded and unstable 
N-CoR protein (Figure 4B) along with significantly higher level 
of Flt3 protein (Figure 4C). As observed with CD34 level, the level 
of Flt3 in non-promyelocytic/monocytic AML-derived HL-60 
and U937 cells was significantly lower when compared with its 
level in promyelocytic and monocytic AML cells (Figure  4C). 
The same inverse correlation between misfolded N-CoR and Flt3/
CD34 level was also observed in multiple primary promyelocytic 
AML patient samples (Figures  5A,B). Moreover, as observed 
with all the monocytic AML-derived cell lines in Figure 4A, the 
CD34 positivity of primary leukemic cells derived from four inde-
pendent monocytic AML patients was also significantly higher 
(Figure 5C). All of these four primary monocytic AML patient 
samples, as shown previously [monocytic AML patient samples 
#8–#11; Figure 2 in Ref. (8)], harbored a distinctly misfolded 
N-CoR protein along with a significantly higher level of Flt3. 
Together, these findings suggest a key role of misfolded N-CoR 
in the up-regulation of Flt3+/CD34+-based stem cell phenotype in 
promyelocytic and monocytic AML cells.
genetic or Therapeutic restoration of n-cor 
conformation suppresses the cD34+/Flt3+-
Based stem cell Phenotype in Promyelocytic 
and Monocytic aMl
Next, to investigate the role of N-CoR in the suppression of stem 
cell phenotype defined by Flt3+/CD34+, monocytic AML-derived 
THP-1 cells were transfected with Flag-tagged N-CoR expression 
FigUre 3 | ectopically expressed n-cor inhibits the growth and repopulating potential of c-Kit+ stem cell/progenitor cells in vivo. 5 × 105 N-CoR or 
control vector-transfected BM cells were transplanted intravenously into sublethally irradiated C57BL/6 mice (8 Gy). The percentage of GFP-positive cells in the 
peripheral blood of transplanted mice was determined by FACS at the intervals of weeks 3 (upper panel) and 6 (lower panel).
FigUre 4 | Misfolded n-cor is correlated to the cD34+/Flt3+-based stem cell phenotype in promyelocytic and monocytic aMl-derived cells. (a) 
Percentage of CD34+ cells in promyelocytic AML (NB4, NB4-R1, and AP1060) or monocytic AML (THP-1, Nomo-1, MV-4-11, SigM5, and MM1) as well as 
non-promyelocytic/monocytic AML cells (HL-60 and U937) as determined by flow cytometry. (B) An aliquot of whole-cell extract prepared from various AML-derived 
cells as mentioned on the top of each lane was resolved in SDS-PAGE and stained with anti-N-CoR antibody. All the CD34+ promyelocytic and monocytic AML cells 
(NB4, THP-1, Nomo-1, MV-4-11, SigM5, and MM1) harbor a distinctly misfolded N-CoR protein as demonstrated by its premature loss in Western blotting. In 
contrast, N-CoR in CD34-negative non-promyelocytic/monocytic AML cells (HL60 and U937) is natively folded and stable. For loading control, an aliquot of 
whole-cell extract was stained with residual protein beta-actin. (c) Level of Flt3 transcript in promyelocytic and monocytic AML (NB4, THP-1, Nomo-1, MV-4-11, 
SigM5, and MM1) and non-promyelocytic/monocytic AML cells (HL60 and U937) was determined by real-time quantitative PCR and plotted as bar graph. The 
values presented are average of three independent experiments.
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plasmid or control vector and any change in CD34 positivity 
was determined by FACS. The 74.6% CD34 positivity of THP-1 
cells was reduced to 58.2% after ectopic expression of N-CoR 
protein, suggesting that ectopic N-CoR may have contributed 
to a relatively moderate level of CD34 reduction in THP-1 cells 
(Figure  6A). This finding is in agreement with our previously 
published data that showed similar reduction in Flt3 level by 
ectopic N-CoR in N-CoR-transfected THP-1 cells (8). To define 
further the role of N-CoR in the regulation of Flt3+/CD34+-based 
stem cell phenotype in promyelocytic and monocytic AML, we 
took advantage of genistein, a soy extract that effectively restored 
the native N-CoR conformation and function in promyelocytic 
and monocytic AML (7–9). As expected, genistein caused a 
dose-dependent reduction of CD34 positivity in THP-1 cells 
(Figure  6B). The reduction of CD34 positivity in THP-1 cells 
by genistein was most noticeable at 50 μM concentration, the 
same dose that most effectively stabilized the native N-CoR con-
formation and down-regulated the Flt3 level in THP-1 cells (8). 
These findings suggest a significant correlation between N-CoR 
conformation and Flt3+/CD34+-based stem cell phenotype in 
promyelocytic and monocytic AML cells.
Discussion
Dynamic regulation of transcription of self-renewal and lineage-
specific genes by transcriptional factors and their associated co-
factors play a major role in hematopoietic lineage determination, 
differentiation, as well as in the development of LSCs in AML. 
Although recent advances in the field of hematopoietic stem cell 
research has greatly improved our understanding about the role 
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of specific transcription factors in the regulation of HSCs’ growth 
and lineage specification as well as their involvement in specific 
AML subtypes, very little is known about how the function of tran-
scriptional co-factors, especially those involved in transcriptional 
repression, is modulated to allow selective temporal or spatial 
expression or suppression of various stage or lineage-specific 
genes in normal hematopoiesis and in AML. It is likely that these 
transcriptional co-factors may also play fundamental roles in the 
development and growth of normal as well as LSC phenotypes 
through their spatial and temporal regulations of self-renewal and 
lineage-specific genes in normal hematopoiesis and in leukemia. 
Based on this premise, we investigated the role of N-CoR, a key com-
ponent of the generic transcriptional repressor complex essential 
for the transcriptional repression meditated by various transcrip-
tional factors involved in normal hematopoiesis and in leukemia. 
The finding presented in this article, for the first time, identified 
key roles of native and misfolded N-CoR in hematopoietic stem 
cells development and in the formation of subtype-specific LSCs 
defined by myeloid antigen-based stem cell marker CD34 and the 
expression of key self-renewal gene Flt3. Based on the findings 
presented in this article, we can postulate that lack of expression 
of N-CoR in primitive hematopoietic cells may allow these cells to 
generate a stem cell niche by facilitating the unhindered expression 
of stem cell self-renewal genes like Flt3. However, as the primi-
tive hematopoietic cells proceed toward maturation, the gradual 
increase in N-CoR expression would actively repress the Flt3, 
leading to suppression of cellular self-renewal potentials and down 
regulation of CD34 level, which will facilitate the commitment and 
maturation of primitive hematopoietic cells to myeloid lineage. 
Owing to the misfolding and premature loss of N-CoR protein in 
promyelocytic and monocytic AML cells, the repressive control of 
N-CoR on Flt3 will be lost, which would lead to up-regulation of 
Flt3 and eventual reactivation of the Flt3+/CD34+-based stem cell 
phenotype in promyelocytic and monocytic AML.
The possible role of misfolded N-CoR in the development of 
LSCs, as described by us in this report, might be surprising but not 
quite unexpected. The pathways linked to N-CoR misfolding have 
already been known to play important role in AML pathogenesis 
and has recently been identified to play a key role in the growth 
and development of LSC phenotypes as well. For example, Akt, 
which is linked to N-CoR misfolding through its kinase activity 
(9), has recently emerged as an important regulator of cancer stem 
cell growth and development. Both promyelocytic and monocytic 
AML are characterized by reversible differentiation blockage in 
which a crucial role of Akt has recently been identified (26). In a 
recently published study, selective Akt activation was observed in 
a subset of CD34+ cells when primary AML cells were treated with 
stem cell factor (27). In another study, the kinase activity of Akt 
was associated with the proliferation of stem cell-like cancer cells 
(28). A role of Akt in the enhancement of self-renewal potentials of 
human pluripotent stem cells in response to Wnt signaling was also 
recently identified (29). These findings, along with our previous 
FigUre 5 | Misfolded n-cor is correlated to the cD34+/Flt3+-based stem cell phenotype in promyelocytic and monocytic aMl primary patient 
samples. (a,c) Percentage of CD34+ cells in promyelocytic AML (a) and monocytic AML (c) primary patient samples was determined by flow cytometry.  
(B) Level of N-CoR and Flt3 proteins in promyelocytic AML primary patient samples used in (a). HL60 and THP-1 cells were used as positive and negative control 
for N-CoR protein respectively.
FigUre 6 | native n-cor down regulates the cD34 positivity in monocytic aMl cells. (a) Ectopic overexpression of N-CoR in THP-1 cells reduced the 
CD34+ positivity as determined by flow cytometry. (B) Genistein decreased the percentage of CD34+ positivity of THP-1 cells in a dose-dependent manner.
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report demonstrating a key role of Akt in N-CoR misfolding (9), 
suggest that Akt activation may act as a bridge between the extra-
cellular oncogenic stimulus and N-CoR-based transcriptional 
machinery to dynamically regulate the expression of self-renewal 
genes during normal hematopoiesis and AML pathogenesis.
Although AML has long been recognized as a stem cell 
disorder, the origin of LSC in AML was always a matter of 
intense debate. Owing to the conflicting reports emerging from 
seemingly identical studies, both HSCs and committed myeloid 
cells were proposed as the seed of LSCs in AML. In the stem cell 
origin of cancer model, it was postulated that since these cells 
already possess unlimited self-renewal and proliferative poten-
tials, any oncogenic alteration introduced in these cells will have 
better chance of transforming the cells in the long run. Another 
argument in favor of stem cell origin of cancer model in AML is 
their significantly longer life span, which would naturally allow 
significantly higher number of oncogenic aberrations to accumu-
late in the mutant clone in due course of time. The committed 
myeloid cells, in contrast, were considered unlikely candidates of 
LSC or LICs due to their limited life span and their lack of any 
self-renewal and proliferative potentials. However, several elegant 
studies in mice involving the promyelocytic and monocytic 
AML-specific fusion oncogenes demonstrated that these fusion 
oncogenes could initiate full-blown AML only when they were 
expressed in the committed myeloid compartment. Subsequently, 
it was shown that fusion oncogenes linked to promyelocytic and 
monocytic AML may impart or reactivate the stem cell-like 
unlimited self-renewal and proliferative potentials in committed 
cells, leading to the formation LSCs in the long run (13–17). 
However, the molecular mechanism underlying the reactivation 
of stem cell-like properties in the committed myeloid cells was 
largely unknown. The finding presented in this article, for the first 
time, identified misfolded N-CoR as the key factor linked to the 
ectopic reactivation of certain stem cell phenotypes in specific 
subtypes of AML and provided a novel mechanistic insight into 
the possible origin of LICs or LSCs in AML.
Although considerable progress has been made in the identi-
fication and characterization of stem cell populations in normal 
and malignant tissues, differentiating the LSCs from its normal 
counterpart for tangible diagnostic or therapeutic application 
is still a daunting task technically. Currently known genetic, 
immune-phenotypic, and functional characteristics based on 
which hematopoietic stem cells are characterized are also present 
in LSCs derived from various AML subtypes and therefore are not 
suitable for selective identification and targeting of LSC popula-
tions in AML. Identification and characterization of biomarkers 
that could differentiate the LSCs from the normal hematopoietic 
stem cell populations are not only important for understanding 
the biological process of stem cell growth but are also crucial for 
the design and development of highly selective and less toxic 
therapeutic approaches for AML. Based on the status of N-CoR 
protein, AML could be classified into two broader subgroups: 
one that originated in the stem cell compartment and have an 
intact N-CoR protein and the other that has its origin in rela-
tively matured cells which harbor a misfolded and functionally 
redundant N-CoR protein. Identification and characterization of 
misfolded N-CoR protein as a molecular target and as a subtype 
specific biomarker of AML will facilitate better understanding of 
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the molecular mechanisms underlying AML pathogenesis and 
will provide a common diagnostic and therapeutic target across 
all promyelocytic and monocytic AML variants.
experimental Procedures
cell lines, antibodies, and reagents
The monocytic AML cell lines [THP-1, Mono-Mac-1 (MM1), 
Nomo-1, and MV4-11], non-monocytic AML cell lines (U937 and 
HL-60), and promyelocytic AML cell line (NB4) were maintained 
in RPMI 1640 medium (Life Technologies, Gaithersburg, MD, 
USA) supplemented with 10% fetal bovine serum (FBS; Hyclone 
Laboratories, Logan, UT, USA), 100 U/ml penicillin, and 100 U/ml 
streptomycin in a humidified atmosphere of 5% CO2. The AML-
M5 cell line SigM5 was maintained in Isocove’s modified medium 
(Life Technologies, Gaithersburg, MD, USA) supplemented with 
20% FBS. The N-CoR (C-20) (goat polyclonal) antibody was pur-
chased from Santa Cruz Biotechnology (CA, USA) and used as 
described previously (6, 7). Flt3 (C-20) antibody was purchased 
from Santa Cruz Biotechnology (CA, USA) while PE-conjugated 
anti-mouse c-kit antibody was purchased from Pharmingen (San 
Diego, CA, USA). N-CoR-stabilizing agent genistein was used as 
previously described (6, 7). Phoenix-Eco packaging cell line was 
a kind gift from Dr. Motomi Osato (Cancer Science Institute of 
Singapore, NUS, Singapore).
Patients and Primary leukemic sample 
Preparation
Primary leukemic samples used in this study were obtained at the 
time of diagnosis. Diagnoses of AML were made from the morphol-
ogy and cytochemistry according to the French–American–British 
(FAB) classification as well as immunophenotypic and cytogenetic 
analyses. Mononuclear cells were isolated from the peripheral 
blood or bone marrow samples. This study was approved by the 
Institutional Review Board and IACUC (institutional animal 
care and use committee) of National University of Singapore. For 
human samples used in the study, informed consent was obtained 
from the patients in accordance with the Declaration of Helsinki.
retrovirus Production and infection of Bone 
Marrow cells
Mouse N-CoR cDNA was cloned into the retroviral vector MIG 
[MSCV/Internal ribosomal entry site (IRES)/green fluorescent 
protein (GFP)]. After 2 weeks of selection with diphtheria toxin 
(1 mg/ml) and hygromycin (0.36 U/ml), approximately 2 × 107 
Phoenix-Eco packaging cells were transfected with 60 μg MSCV-
N-CoR using FuGENE®6 (Roche Diagnostics, Basel, Switzerland). 
Supernatants were collected 24 and 48 h after transfection and 
centrifuged at 12,000 rpm at 4°C overnight. The retrovirus pel-
let was resuspended in 0.5  ml α-minimum essential medium 
(α-MEM; Gibco, CA, USA). Wild-type C57BL/6 mice were 
injected intraperitoneally with 2.5  mg of 5-fluorouracil (5-FU; 
Sigma-Aldrich, MO, USA) essentially as described (30). Five 
days after injection, BM cells were collected from limbs of mice 
by flushing media through the marrow of the bones, and 3 × 106 
cells were cultured in 2 ml of α-MEM supplemented with 10% 
FBS, 1% antibiotic-antimycotic (Gibco, CA, USA), and 10 ng/ml 
recombinant murine interleukin-3 (IL-3), 20 ng/ml interleukin-6 
(IL-6), and 10 ng/ml stem cell factor (SCF, all cytokines are from 
Pepro Tech EC Ltd, USA). The collected retrovirus was added to 
the cells at day 2 and day 3 with 50 μg RetroNectin (TAKARA, 
Japan), and spin infection of the cells was done at 2000  rpm 
at 30°C for 2  h. The cells were sorted by multiparametric flow 
cytometry using the FACS Vantage cell sorter (BD Biosciences, 
CA, USA).
colony-Forming Unit-culture assay
1 ×  104 GFP- and c-Kit-positive cells were cultured in 35-mm 
plates in 1  ml methocult M3131 methylcellulose medium 
(StemCell Tec., Canada) containing 1% antibiotic-antimycotic 
supplemented with 10 ng/ml recombinant murine IL-3, 10 ng/ml 
SCF, 100 ng/ml G-CSF, and 10 ng/ml EPO. To compare and quan-
tify the colony formation (one colony consisting of more than 
30 cells) capacity of N-CoR or vector-infected cells, the number 
of granulocyte (G), macrophage (M), granulocyte–macrophage 
(GM), and mixed colonies (granulocyte, erythroid, monocyte, 
and megakaryocyte) was scored and plotted as bar graph.
long-Term culture-initiating cell assay
1 × 104 GFP- and c-Kit-positive cells were cultured for 18 days 
in a six-well plate on an OP9 stromal cell layer in 2 ml αMEM 
medium supplemented with 10% FBS, 1% antibiotic-antimycotic, 
and 10  ng/ml recombinant murine IL-3, 100  ng/ml G-CSF, 
10  ng/ml SCF, and 10  ng/ml EPO (Pepro Tech EC Ltd, USA). 
Hematopoietic cells were then harvested and subjected to 
Wright–Giemsa staining for morphological analysis.
Quantitative real-Time rT-Pcr
Total RNA was isolated using the RNeasy Mini Kit (Qiagen 
GmBH, Hilden, Germany). From each sample, 2 μg of RNA was 
converted into cDNA by oligo(dT)18-primed reverse transcription 
using SuperScript II RT First-Strand kit (Invitrogen, Carlsbad, 
CA, USA) as described by the manufacturer. The cDNA was 
subject to semiquantitative PCR analysis using Accuprime Taq 
polymerase system (Invitrogen, Carlsbad, CA, USA) according 
to manufacturer’s recommendations. Flt3 primers were used as 
previously described in Ref. (8).
Detection of cD34 cell surface antigen
Cell cultures and patient samples were collected, washed twice 
with PBS + 0.5% bovine serum albumin, and incubated for 10 min 
on ice in 1 ml of PBS + 0.5% bovine serum albumin with 2 μg/
ml propidium iodide (Pharmingen, San Diego, CA, USA) and 
FITC-conjugated monoclonal mouse anti-human CD34 antibody 
(1:100 dilution) or control IgG (1:100 dilution) (Miltenyi Biotech, 
Auburn, CA, USA). Antibody-conjugated cells were washed with 
PBS + 0.5% bovine serum albumin and analyzed using FACS.
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